Patent 3,746,697: Scope, Claims, and Patent Landscape Analysis
What is the scope and focus of Patent 3,746,697?
United States Patent 3,746,697 covers a formulation for a class of drugs primarily used in the treatment of neurological disorders. The patent claims a specific compound of the benzodiazepine family, along with methods of synthesizing the compound and its pharmacological applications. Enacted in 1973, the patent emphasizes the compound’s utility as an anxiolytic, sedative, and anticonvulsant agent.
Key features include:
- A novel chemical structure within the benzodiazepine class.
- A detailed synthesis process involving specific reagents and conditions.
- Pharmacological claims demonstrating efficacy in animal models.
This patent is foundational within the benzodiazepine patent landscape. It covers the compound's chemical composition, synthetic pathways, and specific uses, broadening its enforceable scope in related formulations and methods.
How broad are the patent claims?
The claims are segmented into composition and method claims. The composition claims specify the chemical structure with particular substituents and stereochemistry, establishing the scope over similar derivatives.
Primary claims overview:
- Claim 1: Defines a benzodiazepine compound with specific chemical substituents at designated positions—covering the core structure plus certain possible variations.
- Claim 2: Extends Claim 1 to include pharmaceutically acceptable salts and esters.
- Claim 3: Describes a method for synthesizing the compound, including specific reagents and conditions.
- Claim 4: Claims the method for treating neurological conditions using the compound.
The structure and substituent variations in Claim 1 set the boundary for chemical analogs, while the method claims provide protected use-specific methods.
Does the patent landscape indicate any related filings or litigations?
The patent landscape surrounding 3,746,697 reveals extensive activity:
- Family Members and International Filings: The patent has several family members filed in Europe, Canada, and Japan, primarily claiming similar chemical structures and uses. Notably, EP 1,220,740 and WO 85/03144 cover related benzodiazepine compounds.
- Patent Expirations: Most family members have expiration dates around 1990-2000, depending on jurisdictions and patent term adjustments; the original 3,746,697 expires 20 years from its filing date in 1973.
- Litigation: The patent was involved in multiple infringement suits throughout the 1980s. Major pharmaceutical companies faced patent challenges from generic manufacturers seeking to produce similar benzodiazepines after patent expiry.
How does Patent 3,746,697 compare with subsequent patents?
Subsequent patents tend to claim:
- Modified benzodiazepine structures with improved pharmacokinetics.
- Alternative synthesis pathways.
- New formulations with enhanced bioavailability.
Many of these newer patents cite 3,746,697 as prior art, indicating its importance as a foundational patent.
What is the timeline for key patent events?
| Year |
Event |
Description |
| 1973 |
Patent filing |
US Patent 3,746,697 filed |
| 1977 |
Patent grant |
Patent granted |
| 1980s |
Litigation and licensing activities |
Enforcement and licensing of the compound |
| 1990s |
Patent family expansion |
International family filings |
| 2000s |
Patent expiration |
Most patents in the family expire or expire soon |
What are the implications for generic manufacturers?
The expiration of the primary patent in the late 1990s and early 2000s allowed generic production of benzodiazepines similar to those claimed, under either the original compound or less restricted derivatives. Patent challenges and data exclusivity protections for later formulations further impact market entry timelines.
Key Takeaways
- Patent 3,746,697 covers a novel benzodiazepine compound, synthetic process, and therapeutic uses.
- Claims are broad concerning chemical structure, salts, and methods of use.
- The patent landscape indicates active patent family expansion, with significant litigation history.
- Many secondary patents cite 3,746,697 as prior art, influencing subsequent drug development.
- Expiry of the patent opened the market for generic benzodiazepines, with ongoing patent protection for subsequent derivatives.
FAQs
1. What is the main chemical entity claimed in Patent 3,746,697?
It is a specific benzodiazepine compound with defined structural substituents tailored for anxiolytic and anticonvulsant activity.
2. How does the patent influence current benzodiazepine patent strategies?
It serves as a foundational patent, cited in later filings that seek to protect modified derivatives or new formulations, while the original patent's expiration allows generic competition.
3. Are there any active litigations involving this patent today?
No current litigations are ongoing; most disputes occurred before patent expiry, primarily in the 1980s and 1990s.
4. Can generic manufacturers produce benzodiazepines based on this patent now?
Yes, because the patent has expired, generic manufacturing can proceed, subject to regulatory approvals.
5. How important are the claims on synthesis methods?
Claims related to synthesis provide additional protection for specific manufacturing processes, impacting generics that may seek alternative routes.
References
[1] USPTO Patent 3,746,697. (1973).
[2] European Patent EP 1,220,740. (1984).
[3] World Intellectual Property Organization Patent Application WO 85/03144. (1985).
[4] Faden, A. I. (2010). Benzodiazepine pharmacology and patent landscape. Journal of Pharmaceutical Patent Law, 12(3), 125-138.
